Skip to main content
. 2021 Dec 14;13(24):6275. doi: 10.3390/cancers13246275

Figure 3.

Figure 3

Overview of systemic treatment options in recurrent endometrial cancer. ER: estrogen receptor; PR: progesterone receptor; MMR-D: mismatch repair deficient; MSI: microsatellite instability; MSS: microsatellite stable; pMMR: proficient mismatch repair; PFS: progression-free survival; OS: overall survival. * Preferably histology on recurrent tumor ** also approved for pMMR/MSS *** Dependent on level of expression.